New Board Members to Bolster Strategic Growth

Clinical diagnostics company Symcel has announced two key appointments to boost its strategic growth in both the research market and in clinical diagnostic solutions development.

Internationally recognised for his success in building prosperous life science companies, Erik Walldén will play a pivotal role in the implementation of the company’s business, sales and marketing strategies and help it develop a larger international network of contacts and prospects. Stefan Löfås will add strong scientific expertise and experience in the valuation and acquisition of companies that will be used for assessing potential partnership opportunities.

During 30 years of international life science industry management, Erik has been responsible for the global launch of a number of technologies, establishing and restructuring companies, implementation of targeted issues and stock market listings. He was previously the CEO of Gyros, Affibody Holding, Biacore International and Pyrosequencing and has held senior positions at PerSeptive Biosystems, Pharmacia Biosensor and Pharmacia Biotech. Stefan was the Chief Scientific Officer at Biacore International and until recently the Scientific Director at GE Healthcare Bio-Sciences with strategic responsibility for technology development.

“We are delighted that both Erik Walldén and Stefan Löfås are joining the board. Their appointments will play a crucial role in the realisation of the ambitious corporate strategy that we set ourselves – enabling Symcel to increase the flow of business from the R&D sector and expand into the clinical diagnostics space,” commented CEO Jesper Ericsson.